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ABBREVIATIONS: 6MWD = 6-minute walking distance; ADMA = asymmetric dimethylarginine; AE = 
adverse event; AMBITION = Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension; 
ASL = argininosuccinate lysase; ASS = argininosuccinate synthase; BH2 = dihydrobiopterin; BH4 = 
tetrahydrobiopterin; BMPR-2 = bone morphogenetic protein receptor-2; cGMP = cyclic guanosine 
monophosphate; CHEST-1 and -2 = CHronic thromboEmbolic pulmonary hypertension sGC-Stimulator 
Trial-1 and -2; Cmax = maximum plasma concentration; CO = cardiac output; COPD = chronic obstructive 
pulmonary disease; CTEPH = chronic thromboembolic pulmonary hypertension; DBP = diastolic blood 
pressure; DDAH = dimethylarginine dimethylaminohydrolase; eNOS = endothelial nitric oxide synthase; 
EQ-5D = EuroQol 5 Dimensions questionnaire; ERA = endothelin receptor antagonist; FC = functional 
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class; GMP = guanosine monophosphate; GTP = guanosine triphosphate; HFpEF = heart failure with 
preserved ejection fraction; HIV = human immunodeficiency virus; HR = heart rate; ILD = interstitial lung 
disease; iNOS = inducible nitric oxide synthase; LPH = Living with Pulmonary Hypertension 
questionnaire; LS = least squares; MLHF = Minnesota Living with Heart Failure questionnaire; mPAP = 
mean pulmonary artery pressure; NADPH = nicotinamide adenine dinucleotide phosphate; nNOS = 
neuronal nitric oxide synthase; NO = nitric oxide; NOS = nitric oxide synthase; NT-proBNP = N-terminal 
prohormone of brain natriuretic peptide; O2
–
 = superoxide anion; PAH = pulmonary arterial 
hypertension; PATENT-1 and -2 = Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 and -2; PCWP 
= pulmonary capillary wedge pressure; PDE = phosphodiesterase; PEA = pulmonary endarterectomy; PH 
= pulmonary hypertension; PH-ILD = PH associated with interstitial lung disease; PH-sLVD = PH due to 
systolic left ventricular dysfunction; PKG = cGMP dependent protein kinase; PVR = pulmonary vascular 
resistance; QoL = quality of life; RAP = right atrial pressure; RV=right ventricle; RVED = right ventricular 
end-diastolic; SAE = serious adverse event; SBP = systolic blood pressure; SD = standard deviation; sGC = 
soluble guanylate cyclase; SEM = standard error of the mean; SERAPHIN = Study with an endothelin 
Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical outcome; sGC = soluble 
guanylate cyclase; SV = stroke volume; SVI = systemic vascular index; SvO2 = mixed venous oxygen 
saturation; SVR = systemic vascular resistance; WHO = World Health Organization 
Running head:  
Riociguat mode of action clinical review 
Keywords:  
Pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, sGC stimulator  
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Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) 
are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary 
vasculature, leading to elevated pulmonary artery pressure and increased pulmonary vascular 
resistance. If untreated, they can result in death due to right heart failure. Riociguat is a novel soluble 
guanylate cyclase (sGC) stimulator that is approved for the treatment of PAH and CTEPH. Here we 
describe in detail the role of the nitric oxide–sGC–cyclic guanosine monophosphate (cGMP) signaling 
pathway in the pathogenesis of PAH and CTEPH, and the mode of action of riociguat. We also review the 
preclinical data associated with the development of riociguat, along with the efficacy and safety data of 
riociguat from initial clinical trials and the pivotal Phase III randomized clinical trials in PAH and CTEPH. 
Abstract: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension 
(CTEPH) are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary 
vasculature, leading to elevated pulmonary artery pressure and increased pulmonary vascular 
resistance. If untreated, they can result in death due to right heart failure. Riociguat is a novel soluble 
guanylate cyclase (sGC) stimulator that is approved for the treatment of PAH and CTEPH. Here we 
describe in detail the role of the nitric oxide–sGC–cyclic guanosine monophosphate (cGMP) signaling 
pathway in the pathogenesis of PAH and CTEPH, and the mode of action of riociguat. We also review the 
preclinical data associated with the development of riociguat, along with the efficacy and safety data of 
riociguat from initial clinical trials and the pivotal Phase III randomized clinical trials in PAH and CTEPH. 
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Introduction 
According to the current World Health Organization (WHO) classification, five categories of pulmonary 
hypertension (PH) exist: pulmonary arterial hypertension (PAH; Group 1), PH resulting from left heart 
disease (Group 2), PH due to hypoxia and/or disorders of the respiratory system (Group 3), chronic 
thromboembolic pulmonary hypertension (CTEPH; Group 4), and PH with unclear/multifactorial 
mechanisms (Group 5) (Table 1).
1
 PH is defined as a mean pulmonary artery pressure ≥ 25 mmHg. PAH 
and CTEPH are progressive pulmonary hypertensive diseases that usually lead to extensive pulmonary 
vascular remodeling, causing a marked increase in pulmonary vascular resistance that leads to right 
ventricle overload, and death when untreated.
2,3
  
Endothelial dysfunction of the pulmonary vasculature plays a key role in the progression of PAH and is 
characterized by impaired production of vasodilators such as nitric oxide (NO) and prostacyclin, and 
overexpression of vasoconstrictors such as endothelin-1, leading to elevated vascular tone and 
promotion of vascular remodeling.
4
 These observations have underpinned three therapeutic target 
pathways in PAH: the prostacyclin pathway (eg, prostanoids such as epoprostenol, iloprost, treprostinil); 
the endothelin pathway (eg, endothelin receptor antagonists [ERAs] such as bosentan, ambrisentan, 
macitentan); and the cyclic guanosine monophosphate (cGMP) degradation pathway (eg, 
phosphodiesterase-5 [PDE5] inhibitors such as sildenafil and tadalafil).
2,3,5
 Despite the availability of 
numerous treatment options, mortality rates in patients with PAH remain high.
6-10
  
Pulmonary endarterectomy (PEA) is the gold standard treatment for CTEPH as it is potentially curative, 
making CTEPH the only form of PH that is curable.
2,3,11,12
 However, 24–37% of patients with CTEPH are 
ineligible for PEA, and 17–35% develop persistent/recurrent PH after PEA.
13-19
 These patients are 
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candidates for medical therapy.
2,3
 Balloon pulmonary angioplasty may also be considered in patients 
with CTEPH who are technically inoperable or have an unfavorable risk:benefit ratio for PEA.
2,3
  
Riociguat, a soluble guanylate cyclase (sGC) stimulator, is approved for the treatment of both PAH and 
inoperable CTEPH or persistent/recurrent CTEPH after PEA.
2,3
 Riociguat adds sGC stimulation as a fourth 
therapeutic target in PAH.
5
 Here we review the mode of action of riociguat, its clinical efficacy, and its 
safety in PAH and CTEPH. 
The role of the NO–sGC–cGMP signaling pathway in PH  
NO is a key regulator of flow-induced vasodilation in the lung (Fig 1).
20-22
 In the healthy lung, NO is 
produced by the vascular endothelium, airway and alveolar epithelial cells, and diffuses to the smooth 
muscle layer, where it binds to a prosthetic heme group on sGC.
20,21
 Upon binding with NO, sGC 
catalyzes the synthesis of the secondary messenger cGMP from guanosine triphosphate
23
 leading to 
activation of cGMP dependent protein kinase (PKG) which acts through a variety of mechanisms to 
reduce intracellular calcium concentrations and inhibit smooth muscle cell contraction.  
A reduction in endogenous NO levels has been observed in patients with PAH, CTEPH, and PH associated 
with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).
20
 Levels of exhaled 
NO have also been shown to be reduced in patients with idiopathic PAH and PAH associated with 
scleroderma.
24,25
 NO levels are also reduced in conditions of oxidative stress,
26
 biomarkers of which are 
increased in the lungs of patients with idiopathic PAH, PH associated with left heart disease, and 
hypoxia-induced PH.
27-29
 The primary route of NO synthesis is the oxidation of the amino group of L-
arginine, a multiple-step chemical reaction that is catalyzed by NO synthases (NOS) with the assistance 
of several cofactors, such as tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide 
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phosphate (NADPH) (Fig 1). The NOS family consists of endothelial and neuronal NOS (eNOS, nNOS) that 
are constitutively expressed, and inducible NOS (iNOS) that is capable of being stimulated by a variety of 
environmental signals. NO synthesis can be impaired by decreased availability of L-arginine, NOS, or NOS 
co-factors. All three abnormalities have been reported in PAH and CTEPH, and are associated with 
disease progression and poor outcomes.
20,30-32
 Decreased L-arginine levels can occur from increased 
activity of arginase, an enzyme that metabolizes L-arginine to ornithine. Alternatively, elevated levels of 
asymmetric dimethylarginine (ADMA), which competes with L-arginine for NOS binding sites but does 
not activate the enzyme, can impair NO synthesis.
33
   
There is also evidence that eNOS expression and activity are dysregulated in PAH. Studies have shown 
both decreased eNOS expression in small pulmonary arteries and increased eNOS expression in the 
plexiform lesions of patients with PAH.
34,35
  Mice with genetically engineered suppression of caveolin, an 
endothelial membrane protein that binds eNOS and suppresses its activity, have increased eNOS activity 
and develop PH.
36
 This seemingly paradoxical finding may be explained by the observation that NO 
synthesis may be impaired by eNOS over-activity. This occurs because of depletion of the co-factors (eg, 
BH4) that act as electron donors and are necessary for complete oxidation of the L-arginine amino 
group. In the absence of adequate co-factors, or in the presence of substrate deficiency, NO synthesis by 
eNOS becomes uncoupled, leading to decreased synthesis of NO and increased production of reactive 
oxygen species, which contribute to vascular pathology.
22
  
Changes in NO–sGC–cGMP signaling have been implicated in the downstream effects of endothelial 
dysfunction on the pulmonary vasculature, including pulmonary artery smooth muscle cell proliferation, 
vasoconstriction, platelet aggregation and fibrosis, leukocyte recruitment, inflammation, maladaptive 
cardiac hypertrophy, and pulmonary vascular remodeling.
20-22,37,38
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There is increasing interest in the role of genetic factors in PH. Mutations in genes coding for bone 
morphogenetic protein receptor-2 (BMPR-2) are the main cause of heritable PAH.
39
 cGMP-activated PKG 
is a component of the NO signaling pathway downstream of cGMP and plays an important role in BMPR-
2 signaling. Mice with low or absent PKG isotype I exhibit impaired BMP signaling, with decreased 
contractile gene expression and abnormal vascular remodeling.
40
 A mutation in the gene encoding for 
caveolin-1 has also been associated with an increased risk of developing PAH.
41
 
Targeting sGC in PH: Mode of action of riociguat 
Previous attempts to target the NO–sGC–cGMP pathway have focused on preventing cGMP degradation 
by inhibiting PDE5, one of the primary enzymes responsible for cGMP degradation in the lung (Fig 1).  
The PDE5 inhibitors sildenafil and tadalafil have been shown to improve 6-minute walking distance 
(6MWD), WHO functional class (WHO FC), and pulmonary hemodynamics in treatment-naïve patients 
with PAH.
2,3,42,43
  Sildenafil has also been shown to increase 6MWD, reduce pulmonary vascular 
resistance, and delay time to clinical worsening in patients who are already being treated with 
intravenous epoprostenol.
44
 Similarly, tadalafil has been shown to increase functional capacity and delay 
clinical worsening when added to background ERA therapy.
45
 
Registry and long-term extension study data have shown that a proportion of patients with PAH may not 
respond to PDE5 inhibitors alone.
8,46-48
 It is possible that in some of these patients, lack of response is 
due in part to insufficient pulmonary cGMP production.  In mice with decreased cGMP synthesis due to 
disrupted expression of natriuretic peptide receptor A, sildenafil was ineffective at preventing hypoxic 
PH.
49
 Similarly, decreased NO synthesis may restrict the effectiveness of PDE5 inhibitors by reducing the 
pulmonary vascular cGMP levels.
20,50-52
 Results from the Ambrisentan and Tadalafil in Patients with 
Pulmonary Arterial Hypertension (AMBITION) trial and Study with an endothelin Receptor Antagonist in 
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Pulmonary Arterial Hypertension to Improve Clinical outcome (SERAPHIN) have suggested that patients 
on PDE5 inhibitor monotherapy may demonstrate insufficient response to treatment compared with 
patients receiving combination therapy, suggesting that further optimization of the NO–sGC–cGMP 
pathway may be necessary.
53,54
 
To this end, recent efforts have centered on identifying pharmacologic agents that enhance sGC–
induced cGMP synthesis directly.
46,55-57
 
sGC stimulators such as riociguat have a dual mode of action that enhances sGC response to 
endogenous NO and directly stimulates sGC independently of NO binding. In vitro studies have shown 
that riociguat increases the activity of sGC by up to 73-fold and acts in synergy with NO to increase sGC 
activity up to 112-fold.
50
 Thus, these agents circumvent the need for endogenous NO production for 
their mode of action, increasing cGMP levels via a mechanism different to that of PDE5 inhibitors (Fig 
2).20,50,52  
Riociguat: Preclinical data 
The vasodilatory effects of riociguat have been demonstrated in several preclinical models of 
hypertension. Riociguat relaxed isolated saphenous artery rings from normal and nitrate-resistant 
rabbits, and also normalized blood pressure and improved survival in high- and low-renin rat models of 
hypertension.
58
 Moreover, in a Dahl salt-sensitive rat model of malignant hypertension, riociguat 
attenuated systemic hypertension, systolic dysfunction, fibrotic tissue remodeling, and degenerative 
changes in myocardium and renal cortex.
59
 
The beneficial effects on other pathologic processes associated with PH have also been demonstrated in 
several preclinical studies. Administration of riociguat partially reversed PH, right ventricle (RV) 
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hypertrophy, and remodeling of lung vascular tissue in hypoxic mouse and monocrotaline-injected rat 
models.
50
 Similarly, riociguat attenuated bleomycin-induced PH and RV hypertrophy in mice, and to a 
greater extent than sildenafil. Additionally, amelioration of pulmonary inflammation and fibrosis were 
observed with riociguat treatment in the same mouse model.
60
 Furthermore, riociguat has been shown 
to prevent the development of PH, RV hypertrophy, and vascular remodeling compared with controls in 
a cigarette smoke-induced mouse model of COPD and PH.
61
 In a rat model of angioproliferative PAH 
induced by hypoxia and the vascular endothelial growth factor receptor antagonist SU5416, riociguat 
treatment increased the open: occluded artery ratio, decreased the neo-intima: media ratio, reduced RV 
systolic pressure, and increased cardiac output. Moreover, there was a greater decrease in RV 
hypertrophy and increase in RV function than observed following treatment with sildenafil.
62
 The 
antifibrotic effects of riociguat have also been demonstrated, in three separate mouse models of 
fibrosis. Riociguat dose-dependently reduced skin thickening, myofibroblast differentiation, and collagen 
accumulation in the tight skin (TSK-1), and bleomycin-induced models of skin fibrosis; and in a 
sclerodermatous chronic graft-versus-host disease model of systemic sclerosis, riociguat ameliorated 
gastrointestinal tract fibrosis to a greater extent than sildenafil.
63
 The preclinical results observed with 
riociguat led to it becoming the first sGC stimulator to enter clinical development.
56
 
Clinical efficacy of riociguat in PAH and CTEPH 
Riociguat has been evaluated in a number of Phase II studies, and two Phase III studies that enrolled 
patients with PAH (PATENT-1) and inoperable CTEPH or persistent/recurrent CTEPH after PEA (CHEST-1) 
(Table 2). 
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Phase II 
In a single-dose, proof-of-concept study in 19 patients with PH (including patients with PAH, CTEPH, and 
PH with mild-to-moderate ILD), riociguat reduced mean pulmonary artery pressure (mPAP) and 
pulmonary vascular resistance (PVR), and increased cardiac index. Riociguat had no effect on gas 
exchange or ventilation–perfusion matching and was well tolerated.
64
 In an open-label 12-week Phase II 
study that included 33 patients with PAH and 42 patients with CTEPH, riociguat significantly improved 
6MWD, cardiac index, mPAP, PVR, and WHO FC at Week 12 compared with baseline.65 The results from 
the long-term extension to this study show that long-term riociguat treatment (median treatment 
duration: 77 months) was well tolerated, and the improvements in 6MWD and WHO FC were sustained 
for at least 48 months in those patients who continued on riociguat therapy.66 
PATENT 
The Phase III randomized, placebo-controlled PATENT-1 study investigated the safety and efficacy of 12 
weeks of riociguat therapy (up to 2.5 mg three times daily [tid]) in 443 patients with symptomatic PAH. 
The primary endpoint of PATENT-1, change in 6MWD at Week 12, was significantly greater in the 
riociguat 2.5 mg–maximum group compared with placebo (least squares [LS] mean difference +36 m 
[95% CI: 20 to 52], p<0.001).
67
 Riociguat also improved a range of clinically relevant secondary 
endpoints, including PVR (–226 dyn·s·cm
–5
 [95% CI: 20 to 52], p<0.001), N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP; –432 pg/mL [95% CI: –782 to –82], p<0.001), WHO FC (p=0.003), time to 
clinical worsening (p=0.005), and Borg dyspnea score (p=0.002). Several other hemodynamic parameters 
including cardiac output (CO) (+0.9 L/min [95% CI: 0.7 to 1.2], p<0.001), mPAP (–5 mmHg [95% CI: –6 to 
–2], p<0.001), and mixed venous oxygen saturation (SvO2) (+5% [95% CI: 3 to 7], p<0.001) were also 
improved with riociguat versus placebo in PATENT-1.
67
  There was also evidence that the beneficial 
effects of riociguat were reflected in patient quality of life (QoL). Measures of health-related QoL were 
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improved in PATENT-1 (EuroQol 5 Dimensions [EQ-5D] questionnaire score: +0.06 [95% CI: 0.01 to 0.11], 
p=0.07 [minimally important difference (MID), 0.074]
68
; Living with Pulmonary Hypertension 
questionnaire [LPH] score: –6 [95% CI: –10 to –3], p=0.02 [MID, 3 points for subscales, 7 points for total 
score]
69
), with the change in LPH score reaching only nominal significance considering the hierarchical 
testing procedure.
67,70
 The effects of riociguat in PATENT-1 were similar in treatment-naïve patients, and 
in patients receiving riociguat added to a background therapy of ERAs or nonintravenous prostanoids.
67
  
In the PATENT-2 long-term extension study,
71
 after 12 weeks mean 6MWD±SD had changed by +52±61 
m in the former riociguat 2.5 mg–maximum group (n=218) and by +52±67 m in the former placebo 
group, following transition to riociguat (n=103). At the same 12-week time point in PATENT-2, former 
placebo patients showed a decrease in NT-proBNP levels similar to those of former riociguat 2.5 mg–
maximum patients.  
In PATENT-2, improvements in 6MWD, NT-proBNP, WHO FC, Borg dyspnea score, and QoL seen during 
PATENT-1 were sustained for at least 2 years; at 2 years (mean treatment duration 135 weeks) in the 
overall population, mean 6MWD±SD had increased from PATENT-1 baseline by +47±85 m (n=296) and 
WHO FC had improved/stabilized/worsened compared with baseline by 33/58/9% (n=306).
71,72
 The 
estimated survival was 93% at 2 years.
71,72
 
CHEST 
CHEST-1 was a Phase III study of riociguat in 261 patients with inoperable CTEPH or persistent/recurrent 
CTEPH after PEA.
70
 After 16 weeks’ treatment with riociguat (up to 2.5 mg tid), the primary endpoint of 
6MWD increased by 46 m versus placebo (LS mean difference; 95% CI: 25 to 67, p<0.001). Riociguat-
treated patients also showed improvements across a range of clinically relevant secondary endpoints, 
including PVR (–246 dyn·s·cm
–5
 [95% CI: –303 to –190], p<0.001), NT-proBNP (–444 pg/mL [95% CI: –843 
to –45], p<0.001), and WHO FC (p=0.03). The effects of riociguat were consistent although somewhat 
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stronger in patients with inoperable CTEPH compared with those with persistent/recurrent CTEPH after 
PEA.
70
 Riociguat is the first pharmacologic therapy that has been shown to significantly improve both 
6MWD and PVR in patients with inoperable CTEPH and patients with recurrent/persistent CTEPH after 
PEA in a large randomized controlled trial. 
In addition to PVR, other hemodynamic effects of riociguat in the CHEST-1 study were comparable with 
its effects in the PATENT-1 study; CO (+0.9 L/min [95% CI: 0.6 to 1.1], p<0.001), mPAP (–5 mmHg [95% 
CI: –7 to –3], p<0.001), and SvO2 (+4% [95% CI: 1 to 6], p=0.001) were all improved without significant 
changes in heart rate.
67,70
 Nominally significant improvements in health-related QoL were also evident in 
the CHEST-1 study (EQ-5D score: +0.13 [95% CI: 0.06 to 0.21], p<0.001), suggesting that the 
improvements in exercise capacity, hemodynamics, NT-proBNP levels, and WHO FC were translated into 
patient QoL benefits. 
In the CHEST-2 long-term extension study,73 mean 6MWD±SD had increased by +61±59 m after 
12 weeks in the former riociguat group (n=145) and by +51±64 m in the former placebo group, following 
transition to riociguat (n=75). Former placebo patients showed a decrease in NT-proBNP levels similar to 
former riociguat patients at the same time point.   
In CHEST-2, improvements in 6MWD and WHO FC seen during CHEST-1 were sustained for at least 2 
years; at 2 years (mean treatment duration 127 weeks) in the overall population 6MWD±SD had 
increased from CHEST-1 baseline by +50±68 m (n=162) and WHO FC was improved/stabilized/worsened 
in 39/58/3% in the overall population (n=170).
73,74
 Estimated survival was 93% at 2 years.
73
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Clinical safety of riociguat in PAH and CTEPH 
Overall, riociguat was well tolerated in the clinical studies. 
64,65,67,70,75,76
 The most common adverse 
events (AEs) were headache, dizziness, indigestion, peripheral edema, nausea, diarrhea, and vomiting.  
In the 12-week PATENT-1 study, eight (3%) patients receiving riociguat in doses up to 2.5 mg tid 
withdrew due to AEs, while 33 (8%) of the patients who entered PATENT-2 had withdrawn due to AEs by 
the March 2013 cut-off (mean treatment duration 95 weeks).
67,72
 In CHEST-1, four (2%) patients 
receiving riociguat withdrew due to AEs, whereas seven (3%) of the 237 patients who entered CHEST-2 
had withdrawn due to AEs at the March 2013 cut-off (mean treatment duration 83 weeks).
70,73
  
In patients with PH there is an increased likelihood of bleeding, particularly among patients receiving 
anticoagulation therapy.
77
 The total rate of bleeding was not increased with riociguat versus placebo in 
the CHEST-1 and PATENT-1 studies.
67,70
 In the randomized riociguat studies, respiratory tract bleeding 
was reported in 2% of patients treated with riociguat and in 1% of patients treated with placebo. 
Hemoptysis (reported as a serious adverse event [SAE]) was observed in three (2%) riociguat-treated 
patients in CHEST-1 and two (1%) riociguat-treated patients in PATENT-1. In CHEST-2 at 1 year (n=237; 
mean treatment duration 83 weeks), a further three (1%) patients experienced significant hemoptysis 
and one (<1%) patient experienced pulmonary hemorrhage.73 At the same time point in PATENT-2, 
hemoptysis and pulmonary hemorrhage were reported as SAEs in seven (2%) and three (1%) patients, 
respectively (overall population n=396; mean treatment duration 95 weeks).
71
 The mechanism by which 
riociguat could influence the incidence of respiratory tract bleeding is unclear, although bronchial artery 
vasodilation might contribute.  
In PATENT-1, SAEs of syncope occurred in three (1%) patients in the 2.5 mg–maximum group, all of 
which were considered study drug-related, and in five (4%) patients in the placebo group, one (1%) of 
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which was considered study drug-related. In CHEST-1, SAEs of syncope were experienced by four (2%) 
patients in the riociguat group, three (2%) of which were considered study drug-related, and by three 
(3%) patients in the placebo group, of which one (1%) was considered study drug-related. At 1 year of 
both PATENT-2 and CHEST-2, 2% of patients had experienced study drug-related syncope.
71,73
 Renal 
failure was rare in the CHEST or PATENT studies.
67,70,71,73
  
Riociguat: Indication, dosing, and clinical pharmacology 
Riociguat is indicated for the management of PAH and inoperable CTEPH or persistent/recurrent CTEPH 
after PEA in adult patients.
2,3,78,79
 To avoid the risk of hypotension due to the vasodilatory effect of 
riociguat on the systemic circulation, the oral dose is adjusted for the individual patient, guided by the 
signs and symptoms of hypotension. The usual starting dose is 1 mg three times daily (tid) for the first 2 
weeks and the dose is then increased by 0.5 mg tid at 2-week intervals to a maximum of 2.5 mg tid 
based on tolerability (systolic blood pressure ≥ 95 mmHg and no signs or symptoms of hypotension). 
Dose reduction should be considered any time the drug is not tolerated. During Phase III studies, 75% of 
patients with PAH and 77% of those with CTEPH tolerated the maximum dose of 2.5 mg tid.
67,70
 
Oral riociguat is rapidly absorbed with maximum plasma concentrations (Cmax) around 1–1.5 hours and a 
terminal elimination half-life of approximately 12 hours in patients with PAH.78,79 The absolute 
bioavailability of riociguat is approximately 94% and food intake has no clinically relevant effect on 
pharmacokinetics.
78,79
 Pharmacokinetic studies indicate that riociguat has no effect on platelet 
aggregation at clinically relevant concentrations,
80,81
 and has no clinically relevant drug–drug 
interactions with warfarin.
80
 Riociguat can be used in combination with ERAs and/or prostanoids as seen 
in the PATENT study.
67,71
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Concerns over pharmacodynamic interactions between riociguat and PDE5 inhibitors were supported by 
the results of the PATENT PLUS study.
82
 In this 12-week, Phase II study, co-administration of riociguat 
and sildenafil resulted in similar changes in blood pressure as sildenafil plus placebo. However, in the 
long-term extension study, a high rate of discontinuation was observed due to hypotension, and there 
were three deaths (18%) (not considered study drug-related by the investigator). The potentially 
unfavorable safety signals with sildenafil plus riociguat, and no evidence of a positive benefit:risk ratio, 
mean that concomitant administration of riociguat with PDE5 inhibitors is contraindicated.
78,79
 Co-
administration of riociguat with nitrates or NO donors is also contraindicated.
78,79
    
Positioning of riociguat in PAH and CTEPH therapy 
The efficacy data obtained in patients with PAH in the PATENT-1 and PATENT-2 studies led to the 
recommendation in the 2015 ESC/ERS PH treatment guidelines for riociguat as a first-line treatment as 
well as an add-on to background bosentan therapy. Additionally, riociguat is the only pharmacotherapy 
recommended in the 2015 guidelines for the treatment of patients with symptomatic CTEPH that is 
inoperable or persistent/recurrent after surgery.
2,3
 The use of riociguat as first-line therapy in PAH gives 
the option of sequential combination therapy with an ERA or prostanoid to potentially augment the 
benefit experienced by patients. In PATENT-1 it was demonstrated that riociguat provided additional 
efficacy to that achieved with ongoing ERA therapy. Previous studies adding PDE5i to ERA therapy have 
either not met their primary endpoint, or not shown additional benefit.
83-85
  
In PATENT-1 in patients who were treatment-naïve with respect to PAH-specific drugs, riociguat showed 
efficacy in both the primary endpoint and several secondary endpoints.
67,71,72
 Furthermore, there was a 
uniform response pattern between treatment-naïve and pretreated patients, which was not seen in the 
PHIRST trial of tadalafil in PAH.
43
 In addition, the proportion of patients in PATENT-1 fulfilling several 
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responder criteria
86,87
 reflects the clinically meaningful improvements achieved in patients receiving 
riociguat, and suggests that riociguat has a prognostically relevant impact on PAH. Riociguat has also 
been shown to be effective in patients with PAH associated with congenital heart disease,
88
 and in 
patients with PAH associated with connective tissue disease.
89
 
The approval of riociguat for the treatment of PAH adds to a growing armamentarium of medications 
that have recently been approved for this indication.  Although few data are available regarding the 
comparative efficacy of riociguat versus other medications, or which patients are more likely to respond 
to sGC stimulators versus other drug classes, recent studies suggest that patients with PAH do better 
when agents from two or more classes of drugs are combined.
53
  While several choices are available for 
drugs that target the endothelin or prostacyclin pathways, those that target NO/cGMP have been 
limited to PDE5i. The development of riociguat now provides clinicians with another option to augment 
NO–cGMP signaling.  A significant proportion of patients with PAH fail to reach or maintain treatment 
goals with PDE5i. Due to its mode of action, riociguat could potentially overcome these issues and 
provide a possible replacement drug for patients not responding to PDE5i therapy. The ongoing open-
label RESPITE study (NCT02007629) is investigating whether it is safe, feasible, and beneficial to 
transition from PDE5i therapy to riociguat in patients with PAH and an inadequate response to PDE5i, or 
PDE5i in combination with an ERA.
90
 In addition, the different side effect profile of riociguat makes it a 
potential candidate for transition in patients who experience side effects with PDE5i.
42,43,47,48
 
Clinical development of riociguat for other forms of PH 
Endothelial dysfunction and deficits in NO–sGC–cGMP signaling are involved in the progression of 
several subtypes of PH. To this end, a number of Phase II studies with riociguat have been undertaken in 
other forms of PH, including PH associated with systolic left ventricular dysfunction (sLVD),
75,91
 PH 
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associated with heart failure with preserved ejection fraction (HFpEF),
92
 PH associated with ILD,
76
 PH 
associated with COPD (Table 2),
93
 and PH associated with idiopathic interstitial pneumonia.
94
 
Conclusions 
Inadequate signaling of the NO–cGMP pathway may play an important role in the pathogenesis of PAH. 
sGC stimulators such as riociguat offer a novel approach to enhancing NO-mediated cGMP synthesis for 
the treatment of PH (Fig 2). Findings from the Phase III CHEST and PATENT studies indicate that riociguat 
significantly improves exercise capacity and a range of secondary endpoints, including pulmonary 
hemodynamics, NT-proBNP levels, and WHO FC, in patients with inoperable CTEPH and 
persistent/recurrent CTEPH after PEA, and in PAH. Riociguat is effective in treatment-naïve patients with 
PAH and in those who are receiving ERAs and/or prostanoids, and is the only approved medical therapy 
for inoperable or persistent/recurrent CTEPH.  
Stimulating the NO–sGC–cGMP pathway is a promising approach for the treatment of PAH and CTEPH. 
Further studies are needed to identify which patients are most likely to respond favorably to sGC 
stimulation and to determine if patients who do not respond to PDE5 inhibitors or other medical 
therapies for PAH may respond to sGC stimulation.  
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TABLE 1. Classification of Pulmonary Hypertension
1
  
PH Classification Group Features 
1: Pulmonary arterial hypertension 
• Remodeling of the pulmonary vasculature leading to thickened artery walls, 
increased PVR, right ventricle overload, and right heart dysfunction95 
• Can be idiopathic, heritable, induced by certain drugs/toxins or associated with 
other diseases such as connective tissue disease, HIV, portal hypertension, 
congenital heart disease, and schistosomiasis 
 
2: PH due to left heart disease 
• The most common cause of PH
96
 
• Caused by left ventricular systolic or diastolic dysfunction, valvular disease, or 
congenital heart conditions 
3: PH due to lung diseases and/or hypoxia 
• PH occurs commonly in chronic obstructive pulmonary disease and interstitial lung 
disease 
• PH is also associated with sleep-disordered breathing, alveolar hypoventilation 
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disorders, chronic exposure to high altitude, and developmental lung diseases 
4: Chronic thromboembolic pulmonary 
hypertension  
• Characterized by the presence of organized thrombi in the pulmonary vasculature 
and remodeling of unaffected vessels
97
 
• Can be cured surgically by pulmonary endarterectomy
12
 
5: PH with unclear multifactorial mechanisms 
• Includes hematologic disorders such as sickle cell disease, myeloproliferative 
disorders, metabolic disorders, and other conditions such as renal failure 
HIV = human immunodeficiency virus; PH = pulmonary hypertension; PVR = pulmonary vascular resistance. 
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TABLE 2. Overview of Main Clinical Studies with Riociguat 
Study Design Patients Riociguat Dose Key Results Reference 
Phase II proof-of-
concept study 
PAH (n=12) 
CTEPH (n=6) 
PH-ILD (n=1) 
Single 2.5 mg or 1 
mg dose 
Significantly reduced mPAP and PVR, and increased cardiac index 
No effect on gas exchange or ventilation–perfusion matching 
Grimminger et al, 
2009
64
  
Multicenter, open-
label, uncontrolled, 
Phase II study  
PAH (n=33) and 
CTEPH (n=42) 
1.0−2.5 mg ]d for 
12 weeks 
Improved median 6MWD (PAH: +57 m; CTEPH: +55 m; p<0.0001) 
Increased cardiac index (0.43 mmHg; p<0.0001), and reduced mPAP (–4.5 mmHg; p<0.0001), PVR (–215 
dyn·s·cm
–5
; p<0.0001), and SVR (–441 dyn·s·cm
–5
; p<0.0001) compared with baseline 
Ghofrani et al, 
2010
98
 
(NCT00454558) 
Multicenter, open-
label, uncontrolled, 
Phase II long-term 
extension study 
PAH (n=27) and 
CTEPH (n=41) 
1.0−2.5 mg ]d 
Long-term treatment was well tolerated and had a good safety profile 
Sustained improvements in 6MWD for up to a further 45 months (PAH: +80 m; CTEPH: +47 m, 
respectively) 
Hoeper et al, 
2015
66
 
(NCT00454558) 
Randomized, 
double-blind, 
placebo-controlled, 
Phase II interaction 
study (PATENT 
PLUS) 
Patients with 
PAH receiving 
sildenafil (n=18) 
1.0−2.5 mg ]d for 
12 weeks 
No effect of sildenafil plus riociguat on changes in blood pressure vs sildenafil plus placebo 
No evidence of a favorable clinical effect with combination therapy 
High rate of discontinuation due to hypotension in long-term extension 
Galiè et al, 2015
82
 
(NCT01179334) 
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Study Design Patients Riociguat Dose Key Results Reference 
Randomized, 
double-blind, 
placebo-controlled, 
parallel-group, 
multicenter Phase 
IIb study (LEPHT) 
PH-sLVD 
(n=201) 
0.5−2.0 mg ]d for 
16 weeks 
No significant change in mPAP (primary endpoint) 
Cardiac index (+0.4 L·min
–1
·m
–2
; p=0.0001) and SVI (+5.2 mL·m
-2
; p=0.0018) were significantly 
increased with riociguat 2 mg 
PVR (–46.6 dyn·s·cm
–5
; p=0.03) and SVR (–293.3 dyn·s·cm
–5
; p=0.0002) were significantly decreased 
with riociguat 2 mg 
No significant changes in HR or SBP 
MLHF score was significantly improved (p=0.0002) 
Bonderman et al, 
2013
75
 
(NCT01065454) 
Randomized, 
double-blind, 
placebo-controlled, 
single-dose Phase 
IIa study (DILATE) 
PH associated 
with HFpEF 
(n=39) 
Single 0.5−2.0 mg 
dose 
No significant change in peak decrease in mPAP (primary endpoint) 
Riociguat 2 mg significantly increased SV (+9 mL; p=0.04) and cardiac index (+0.4 L/min/m
2
; p=0.001), and 
decreased SVR (–247 dyn·s·cm
–5
; p<0.05) and SBP (–12 mmHg; p=0.03)  
No significant change in HR, PCWP, TPG, or PVR 
Riociguat significantly decreased RVED area (–5.6 cm
2
; p=0.04) 
Bonderman et al, 
2014
92
 
(NCT01172756) 
Phase II proof-of-
concept study 
PH-COPD 
(n=23) 
Single 2.5 mg or 1 
mg dose 
Decreased mPAP (1.0 mg: −3.6 mmHg; 2.5 mg: −4.8 mmHg), PVR (1.0 mg: −58.3 dyn·s·cm
–5
; 2.5 mg: 
−123.8 dyn·s·cm
–5
), SVR (1.0 mg: −440 dyn·s·cm
–5
; 2.5 mg: −468 dyn·s·cm
–5
), SBP (1.0 mg: −26.3 mmHg; 
2.5 mg: −22.2 dyn·s·cm
–5
), and DBP (1.0 mg: −13.5 mmHg; 2.5 mg: −11.3 dyn·s·cm
–5
) 
Slight improvements in lung function 
No change in gas exchange 
Ghofrani et al, 
2015
93
 
(NCT00640315) 
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Study Design Patients Riociguat Dose Key Results Reference 
Multicenter, open-
label, uncontrolled, 
Phase II study 
PH-ILD (n=22) 
1.0−2.5 mg ]d for 
12 weeks plus 12-
month extension 
CO (+1.2 L/min) and SvO2 (+2%) increased, PVR (–120 dyn·s·cm
–5
) and SVR decreased (–821 dyn·s·cm
–5
), 
and mPAP remained unchanged compared with baseline 
6MWD increased by 25 m after 12 weeks; further improvements during follow-up 
Hoeper et al, 
2012
76
 
(NCT00694850) 
Multicenter, 
double-blind, 
randomized, 
placebo-controlled, 
Phase III study 
(CHEST-1) 
CTEPH (n=261) 
1.0−2.5 mg tid for 
16 weeks 
Significant improvements in 6MWD vs placebo at Week 16 (+46 m; p<0.001) 
Significant improvements in PVR (–246 dyn·s·cm
–5
; p<0.001), CO (+0.9 L/min; p<0.001), and mPAP (–5 
mmHg; p<0.001) 
Significant improvements in NT-proBNP (p<0.001) and WHO FC (p=0.003) 
Nominally significant
a
 improvements in Borg dyspnea score and QoL 
Ghofrani et al, 
2013
70
 
(NCT00855465) 
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Study Design Patients Riociguat Dose Key Results Reference 
Multicenter, 
double-blind, 
randomized, 
placebo-controlled, 
Phase III study 
(CHEST-2) 
CTEPH (n=237) 1.0−2.5 mg ]d 
Long-term treatment was well tolerated and had a good safety profile 
Improvements in 6MWD sustained for 1 year (+51 m; n=172) 
Improvements in WHO FC also sustained for 1 year 
Simonneau et al, 
2015
73
 
(NCT00910429) 
Multicenter, 
double-blind, 
randomized, 
placebo-controlled, 
Phase III study 
(PATENT-1) 
PAH (n=443) 
1.0−2.5 mg ]d for 
12 weeks 
Significant improvements in 6MWD vs placebo at Week 12 (+36 m; p<0.001) 
Significant improvements in PVR (–226 dyn·s·cm
–5
; p<0.001), CO (+0.9 L/min; p<0.001), and mPAP (–4 
mmHg; p<0.001) 
Significant improvements in NT-proBNP (p<0.0001), WHO FC (p=0.003), time to clinical worsening 
(p=0.005), and Borg dyspnea score (p=0.002) 
Nominally significant
a
 improvements in QoL 
Ghofrani et al, 
2013
67
 
(NCT00810693) 
Multicenter, 
double-blind, 
randomized, 
placebo-controlled, 
Phase III study 
(PATENT-2) 
PAH (n=396) 1.0−2.5 mg ]d 
Long-term treatment was well tolerated and had a good safety profile 
Improvements in 6MWD sustained for 1 year (+51 m; n=327) 
Improvements in WHO FC also sustained for 1 year 
 
Rubin et al, 2015
71
 
(NCT00863681) 
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Study Design Patients Riociguat Dose Key Results Reference 
a
Due to the hierarchical testing procedure in CHEST-1 and PATENT-1.
67,70
  
6MWD = 6-minute walking distance; CO = cardiac output; COPD = chronic obstructive pulmonary disease; CTEPH = chronic thromboembolic pulmonary hypertension; DBP = diastolic blood 
pressure; HFpEF = heart failure with preserved ejection fraction; HR = heart rate; ILD = interstitial lung disease; MLHF = Minnesota Living with Heart Failure survey; mPAP = mean pulmonary 
artery pressure; NT-proBNP = N-terminal prohormone of brain natriuretic peptide; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; PH = pulmonary 
hypertension; PVR = pulmonary vascular resistance; QoL = quality of life; RVED = right ventricular end-diastolic; SBP = systolic blood pressure; sLVD = systolic left ventricular dysfunction; SV = 
stroke volume; SVI = systemic vascular index; SvO2 = mixed venous oxygen saturation; SVR = systemic vascular resistance; tid = three times daily; TPG = trans-pulmonary pressure gradient; WHO 
FC = World Health Organization functional class. 
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Figure 1 – The NO–sGC–cGMP signaling pathway. The primary route of NO 
synthesis is the oxidation of the amino group of L-arginine, a multiple-step chemical reaction that is 
catalyzed by a family of enzymes known as NO synthases. NO synthases facilitate the oxidation of the L-
arginine amino group with the assistance of several co-factors, notably tetrahydrobiopterin and NADPH. 
NO synthesis can be impaired through decreased availability of L-arginine, NOS or NOS co-factors, or 
increased availability of NOS inhibitors such as ADMA. NO synthesis can also be impaired by eNOS over-
activity as depletion of co-factors results in incomplete oxidation of the L-arginine amino group leading 
to uncoupling of NO synthesis and the generation of reactive oxygen species (see text for details).  
 ADMA = asymmetric dimethylarginine; ASL = argininosuccinate lysase; ASS = argininosuccinate 
synthase; BH2 = dihydrobiopterin; BH4 = tetrahydrobiopterin; cGMP = cyclic guanosine monophosphate; 
DDAH = dimethylarginine dimethylaminohydrolase; eNOS = endothelial nitric oxide synthase; GMP = 
guanosine monophosphate; GTP = guanosine triphosphate; NADPH = nicotinamide adenine dinucleotide 
phosphate; NO = nitric oxide; O2
–
 = superoxide anion; PDE = phosphodiesterase; PKG = cGMP dependent 
protein kinase; sGC = soluble guanylate cyclase.
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Figure 2 – Summary of the mode of action and effects of riociguat.  
cGMP = cyclic guanosine monophosphate; GTP = guanosine triphosphate; NO = nitric oxide; NT-proBNP = N-terminal pro-brain natriuretic 
peptide; sGC = soluble guanylate cyclase. 
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Amended from Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263-2273.
Promotional and commercial use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Wolters Kluwer Health. 
Please contact healthpermissions@wolterskluwer.com for further information
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aReproduced with permission from Rubin LR, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani 
H-A. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) European Respiratory Journal May 2015, 45 (5) 1303-
1313.
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